Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Sep 17;11(11):3193–3204. doi: 10.1111/1759-7714.13642

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Longitudinal analysis of average absolute lymphocyte count (ALC) and platelet count (PLT) according to histopathological type of the primary tumor. Figures (a), (b), and (c) illustrate the longitudinal changes in average ALC in adenocarcinoma (ACC) patients, squamous cell carcinoma (SCC) patients and small cell lung cancer patients (SCLC), respectively () Brain, () Bone, () Control. Figures (d), (e), and (f) illustrate the longitudinal changes in average PLT in ADC patients, SCC patients and SCLC, respectively () Brain, () Bone, () Control. The y‐axis corresponds to the value of the given complete blood count (CBC) parameter, while the x‐axis shows the time frame according to the date of diagnosis of the primary tumor, distant organ metastasis and last follow‐up. The control group consists of stage M0 patients and patients with other distant metastases. The dotted lines represent the linear trendline for each CBC parameter. P‐values for the distant organ metastases and assigned CBC parameters were obtained by the nonparametric Friedman test and Wilcoxon signed‐rank test.

Inline graphic — Longitudinal analysis of average absolute lymphocyte count (ALC) and platelet count (PLT) according to histopathological type of the primary tumor. Figures (a), (b), and (c) illustrate the longitudinal changes in average ALC in adenocarcinoma (ACC) patients, squamous cell carcinoma (SCC) patients and small cell lung cancer patients (SCLC), respectively () Brain, () Bone, () Control. Figures (d), (e), and (f) illustrate the longitudinal changes in average PLT in ADC patients, SCC patients and SCLC, respectively () Brain, () Bone, () Control. The y‐axis corresponds to the value of the given complete blood count (CBC) parameter, while the x‐axis shows the time frame according to the date of diagnosis of the primary tumor, distant organ metastasis and last follow‐up. The control group consists of stage M0 patients and patients with other distant metastases. The dotted lines represent the linear trendline for each CBC parameter. P‐values for the distant organ metastases and assigned CBC parameters were obtained by the nonparametric Friedman test and Wilcoxon signed‐rank test.